Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases
BioPharma Dive
Acquiring Ouro Medicines, which launched last year, hands Gilead an antibody designed to bind to BCMA and CD3, a pair of immune cell proteins that are popular targets for drugmakers.
pharminent
March 24, 2026 (Last updated: March 24, 2026)
BioPharma Dive
Acquiring Ouro Medicines, which launched last year, hands Gilead an antibody designed to bind to BCMA and CD3, a pair of immune cell proteins that are popular targets for drugmakers.